In spite of a list of side effects linked to Onglyza, there is only some success or positive movement at the plaintiff's end. Last year, 14 of them had their claims dismissed by a federal judge in California who granted the defendant AstraZeneca's motion for summary judgment despite a mandate by the FDA to have information about pancreatitis added to the warnings and precautions regarding Onglyza.
The 2009 FDA approved type 2 diabetes medication Onglyza, belongs to a class of DPP-4 inhibitors that control the blood sugar by helping the pancreas to produce more insulin after meals, thereby the amount of glucose produced by the liver is reduced. It was linked to a higher risk of pancreatic cancer and heart failure which became severe allegations faced by the defendants Bristol-Myers Squibb and AstraZeneca.
With our knowledge and expertise, we agree with the notion that there are good chances of an MDL formation as more cases are filed to join the existing lawsuits.
